FibroGen
Gihani Wijewickrama is a Principal Scientist in CMC Analytical Development at FibroGen, Inc., with experience since September 2016, focusing on physicochemical characterization of therapeutic antibodies using platforms such as LCMS, CEX, and SEC. Prior to this role, Gihani served as a Senior Scientist at Genentech South San Francisco and Eurofins Lancaster Laboratory, supporting late-stage therapeutic antibodies through analytical method development and validation, as well as process characterization and validation. Additional experience includes working as a BioAnalytical Scientist at Amgen, providing analytical support for therapeutic antibody characterization, and holding research positions at the University of California, Los Angeles, and the University of Illinois Chicago. Gihani holds a Ph.D. in Chemistry/Biochemistry from the University of Illinois Chicago and a Bachelor of Science with Honors in Chemistry from the University of Kelaniya, Sri Lanka.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.